SYSilvia Yelmo-Cruz

Silvia Yelmo-Cruz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Silvia Yelmo-Cruz has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum Melatonin at Admission and Discharge in Schizophrenia: A Prospective Longitudinal Controlled Study

    by Armando Luis Morera-Fumero, Estefanía Diaz-Mesa, Silvia Yelmo-Cruz, Pedro Abreu-González, María Lourdes Fernández-López

    Schizophrenia is associated with circadian and neuroendocrine disturbances, but whether circulating melatonin changes with acute clinical state remains uncertain. This prospective longitudinal controlled study measured serum melatonin at 12:00 and 00:00 in 43 hospitalized patients after admission and before discharge, and during one session in 42 healthy controls. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Nonparametric comparisons used family-specific Holm adjustment; exploratory correlations used false-discovery-rate control. In comparisons without covariate adjustment, midday concentrations were higher in patients at admission and discharge (Holm p = 0.013 and 0.007), but the differences did not remain significant after Holm correction in exploratory models adjusted for BMI, age, and sex (29 patients and 40 controls). Median within-patient changes were −0.14 pg/mL at 12:00 (95% CI −0.27 to 0.74) and 0.00 pg./mL at 00:00 (95% CI −2.00 to 6.35); both Holm p = 1.000. Total PANSS decreased by a median of 14 points among 24 complete pairs. No change-PANSS correlation survived multiplicity correction. Two daily samples demonstrate a midday–midnight concentration difference but cannot characterize circadian phase, amplitude, or total secretion. No short-term melatonin change was detected during hospitalization; this does not establish equivalence or confirm or exclude trait-biomarker status. State-marker utility remains uncertain, and patient–control differences may reflect medication, smoking, or confounding by assay plate.

  • Open Access

    Longitudinal Changes in Serum Interleukin-33 Levels During Acute Psychotic Relapse and Recovery in Schizophrenia: An Admission-Discharge Study

    by Armando L. Morera-Fumero, José J. Tascón-Cervera, Estefania Diaz-Mesa, Silvia Yelmo-Cruz, Pedro Abreu-González, María Lourdes Fernandez-Lopez

    Immune-inflammatory dysregulation plays a central role in the pathophysiology of schizophrenia (SCZ). Interleukin-33 (IL-33), a pleiotropic alarmin cytokine of the IL-1 family, modulates neuroimmune communication, glial activation, and tissue repair, yet its involvement in psychotic disorders remains poorly characterized. This study examined serum IL-33 concentrations in 21 patients experiencing an acute psychotic relapse and 21 age- and sex-matched healthy controls (HC). Using a longitudinal design, we measured serum IL-33 by ELISA at 12:00 h and 24:00 h on the day after admission and the day before discharge in patients, alongside comprehensive clinical assessment with the Positive and Negative Syndrome Scale (PANSS). Patients with SCZ exhibited significantly lower IL-33 levels than HC at all time points (p < 0.05). Notably, IL-33 concentrations increased significantly at midnight from admission to discharge (p = 0.028), paralleling clinical improvement in PANSS positive and general psychopathology scores. A robust inverse correlation between age and IL-33 levels was observed in both patients and controls (p < 0.05), independent of sex, smoking status, sampling time, and antipsychotic dosage. These findings provide the first longitudinal evidence that IL-33 is reduced during acute psychotic episodes and rises in association with clinical recovery, supporting its role as a state-dependent biomarker. Our results highlight the involvement of alarmin signalling in the neuroimmune dysregulation underlying psychotic relapse and underscore the importance of age as a critical covariate in immunopsychiatric research.

  • Open Access

    Corticosteroid-Induced Psychosis: A Report of Two Cases and Review of the Literature

    by Stefano Canessa-Muñoz, Silvia Yelmo-Cruz, Ana Hamilton-Lopez, Claudia Baez-Marrero

    Glucocorticoids, prescribed for their anti-inflammatory and immunosuppressive effects, are linked to psychiatric side effects, including corticosteroid-induced psychosis. This condition may manifest as affective, organic, or cognitive disturbances, and although the exact pathophysiology is not fully understood, it is believed that corticosteroids impact the hippocampus and hypothalamic-pituitary-adrenal axis, causing neuropsychiatric changes. This report presents two cases of psychosis following corticosteroid use: a 59-year-old man with rheumatoid arthritis and a 62-year-old woman with asthmatic bronchitis. Both cases demonstrated rapid symptom improvement with antipsychotic treatment, emphasizing the need for early intervention. Despite the unclear pathophysiology, corticosteroid-induced psychosis generally has a positive prognosis when promptly managed with drug discontinuation and pharmacological treatment.


  • α-PVP Associated Psychosis

    by Irene Perez-Sagaseta de Ilurdoz, Alicia Aparicio-Dominguez, Silvia Yelmo-Cruz, Cesar Cardenes-Moreno


    • 1 May 2023
      • Vol. 51  (3) , 130-140
    Open Access

    BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) AND FIRST-EPISODE PSYCHOSIS. A LONGITUDINAL ONE-YEAR PROGNOSIS STUDY

    by Silvia Yelmo-Cruz, Armando L. Morera-Fumero, Sunil Lakhwani, Pedro Abreu-Gonzalez

    Introduction. The brain-derived neurotrophic factor (BDNF) is a neurotrophin that has been linked to the schizophrenia neurodevelopmental hypothesis. Several studies confirm that the BDNF levels in first-episode psychosis (FEP) are lower than in healthy controls (HC). However, data about evolution of BDNF levels after a FEP and about the prognostic value of these levels are controversial. Method. Serum BDNF levels at admission of 28 inpatients with FEP were compared with 28 HC. BDNF was also measured at discharge, three, six, nine and twelve months. BDNF levels are presented in ng/ml. We looked for correlation of BDNF levels with the psychotic symptomatology measured with the Positive and Negative Syndrome Scale (PANSS) and also the prognostic value of basal levels was evaluated to predict poor functionality (measured by the Global Assessment of Functioning) and/or relapse, as well as the subsequent diagnosis of a chronic psychotic disorder. Results. At admission, patients BDNF levels were significantly lower than HC levels (18.52 +/- 4.51 vs. 26.55 +/- 3.22, p<0.001). At discharge FEP levels increase until HC levels (25.95 +/- 3.96 vs. 26.55 +/- 3.22, p=0,539). Upon the following determinations, BDNF FEP levels decreased, reaching the admission values, and being significantly lower than the HC and the levels at discharge (patients: three months: 19.68 +/- 3.88; six months: 19.02 +/- 4.13; nine months: 17.64 +/- 5.24; twelve months: 17.51 +/- 3.45 vs. HC: 26.55 +/- 3.22, all p<0.001). A negative correlation was found between admission BDNF levels and the PANSS negative symptoms subscale score with a trend towards significance (r=-0.303, p=0.093). BDNF levels at admission of patients with por functionality and/or relapse at 12 months were lower than BDNF levels of patients with goof functionality and without relapse, this difference had a trend towards significance. (15.38 +/- 4.72 vs. 19.57 +/- 4.06; p=0.071). We didn't found differences between basal BDNF levels of patients who developed a chronic psychotic disorder and patients who didn't. Conclusions. Our results reinforce the neurotrophin hypothesis. Basal levels (at diagnosis) of a FEP could predict the prognosis in terms of functionality and risk of relapse in the first year.


  • Open Access

    Fahr’s Disease: a case report of a patient with neuropsychiatric symptoms

    by I. Perez-Sagaseta, S. Yelmo-Cruz, C. Cardenes-Moreno, L. Torres-Tejera, A. Crisostomo-Siverio, J. Dorta-Gonzalez, J. J. Tascon-Cervera, M. Paniagua-Gonzalez, S. Canessa, M. R. Cejas-Mendez

    Fahr’s disease (FD) is a rare disorder consisting of bilateral and symmetrical calcium deposits in basal ganglia and cerebral cortex. These lesions are associated with neurological and psychiatric symptoms such as a rigid hypokinetic syndrome, mood disorders and memory and concentration abnormalities. It can be idiopathic or secondary to endocrine disorders, infectious diseases or mitochondrial myopathies. To highlight the importance of considering organic causes when evaluating patients presenting atypical psychiatric symptoms and claim the role of neuroimaging. Case report and non-systematic review of literature: sources obtained from Pubmed database. A 69-year-old man, native of Syracuse (Italy), was admitted to the Psychiatry Unit in February 2022 presenting behavioural disturbances and irritability. In July 2021 he presented the same symptoms, being mistakenly diagnosed with Bipolar Disease type I. He has no previous psychiatric history. He started with changes in his personality, short-term memory loss, aggressiveness and disorganized behaviour at the age of 66. At admission he was talkative and hyperfamiliar, presenting delusions of grandiosity, exalted affectivity and insomnia. Neurological examination showed short-term memory problems, signs of frontal disinhibition and abnormal glabellar tap sign. Blood tests, CT brain and MRI were performed to rule out organic underlying causes. Neuro-imaging found bilateral and symmetric calcifications in globus pallidus, thalamus and corpus striatum, in favour of FD. Secondary causes (abnormalities in the PTH, vitamin disorders and infectious diseases such as HIV, brucellosis or neurosyphilis) where discarded, allowing us to conclude it was probably a primary case of FD. Valproate was started as a mood stabilizer and anticonvulsant. Genetic tests were indicated. FD should be considered as a differential diagnosis in the evaluation of psychiatric symptoms, especially when atypical and/or presented with neurological symptoms. The role of neuro-imaging is essential. None Declared

  • Antibiomania

    by Patricia Quandt-Herrera, Javimar Suarez-Jesus, Silvia Yelmo-Cruz


  • S100B and schizophrenia

    by Silvia Yelmo‐Cruz, Morera‐ Fumero, Armando L., Pedro Abreu‐González

    The research for peripheral biological markers of schizophrenia, although abundant, has been unfruitful. In the last 2 decades, the S100B protein has made its own room in this area of research. S100B is a calcium‐binding protein that has been proposed as a marker of astrocyte activation and brain dysfunction. Research results on S100B concentrations and schizophrenia clinical diagnosis are very consistent; patients with schizophrenia have higher S100B concentrations than healthy controls. The results regarding schizophrenia subtypes and clinical characteristics are not as conclusive. Age of patients, body mass index, illness duration and age at onset have been found to show no correlation, a positive correlation or a negative correlation with S100B levels. With respect to psychopathology, S100B data are inconclusive. Positive, negative and absence of correlation between S100B concentrations and positive and negative psychopathology have been reported. Methodological biases, such as day/night and seasonal variations, the use of anticoagulants to treat biological samples, the type of analytical technique to measure S100B and the different psychopathological scales to measure schizophrenia symptoms, are some of the factors that should be taken into account when researching into this area in order to reduce the variability of the reported results. The clinical implications of S100B changes in schizophrenia remain to be elucidated.